140.285  3.125 (2.28%)		09-14 09:45
Open: 141.64 High: 141.64 Volume: 358,914		Pre. Close: 137.16 Low: 140.07 Market Cap: 266,642(M)

Short term
Mid term
Targets	6-month :	179.85	1-year :	192.11
Resists	First :	153.98	Second :	164.47
Pivot price	152.76
Supports	First :	137	Second :	113.99
MAs	MA(5) :	141.96	MA(20) :	153.27
	MA(100) :	151.66	MA(250) :	143.47
MACD	MACD :	-3.6	Signal :	-1
%K %D	K(14,3) :	1	D(3) :	8.7
RSI	RSI(14): 31.4
52-week	High :	165.42	Low :	117.97

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NVS ] has closed above bottom band by 9.7%. Bollinger Bands are 237.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	139.94 - 140.72	140.72 - 141.35
Low:	134.59 - 135.7	135.7 - 136.6
Close:	135.54 - 137.17	137.17 - 138.5

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Fri, 11 Sep 2026
Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline - Yahoo Finance

Fri, 11 Sep 2026
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks - Benzinga

Wed, 09 Sep 2026
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector? - Yahoo Finance

Wed, 09 Sep 2026
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall - Your Wyoming Link

Wed, 09 Sep 2026
Novartis stock downgraded at Deutsche Bank (NVS:NYSE) - Seeking Alpha

Wed, 09 Sep 2026
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS) - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	1,900 (M)
Shares Float	1,860 (M)
Held by Insiders	0 (%)
Held by Institutions	7.2 (%)
Shares Short	4,990 (K)
Shares Short P.Month	5,710 (K)

EPS	6.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	21.86
Profit Margin	22.5 %
Operating Margin	34.6 %
Return on Assets (ttm)	10.2 %
Return on Equity (ttm)	30.3 %
Qtrly Rev. Growth	0.8 %
Gross Profit (p.s.)	22.37
Sales Per Share	29.83
EBITDA (p.s.)	12.15
Qtrly Earnings Growth	-17 %
Operating Cash Flow	18,390 (M)
Levered Free Cash Flow	11,900 (M)

PE Ratio	20.71
PEG Ratio	3.4
Price to Book value	6.27
Price to Sales	4.59
Price to Cash Flow	14.17

Dividend	4.76
Forward Dividend	0
Dividend Yield	3.4%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.